Gender differences in self-reported late effects, quality of life and satisfaction with clinic in survivors of lymphoma. by Arden-Close, Emily et al.
UN
CO
RR
EC
TE
D 
PR
OO
F
Psycho-Oncology
Psycho-Oncology (2010)
Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/pon.1835
Gender differences in self-reported late effects, quality of
life and satisfaction with clinic in survivors of lymphoma
E. Arden-Close1, K. Absolom2, D. M. Greenfield3, B. W. Hancock4, R. E. Coleman4, C. Eiser1 and on behalf of
the Late Effects Group Sheffield
1Department of Psychology, University of Sheffield, Sheffield UK
2Psychosocial Oncology & Clinical Practice Research Group, Level 3, Bexley Wing, St James’ Institute of Oncology, Beckett Street, Leeds, UK
3Sheffield Teaching Hospitals NHS Trust, Weston Park Hospital, Sheffield, UK
4Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, UK
Abstract
Objectives: Gender diﬀerences in perceived vulnerability to late eﬀects and views about follow-up
among cancer survivors have received little attention. As lymphoma aﬀects both genders
similarly, we compared the consequences of cancer (late eﬀects, perceived vulnerability and
quality of life (health-related quality of life (HRQoL)), and satisfaction with clinic visits
between genders.
Methods: A cohort of 115 younger adults (18–45 years,45 years disease-free survival), who
had been treated for lymphoma participated. Questionnaires (n5 91) were completed before
and after (n5 62) routine consultant-led appointments. Survivors (n5 24) without appoint-
ments were recruited by post. Questionnaires included HRQoL, late eﬀects, perceived
vulnerability, issues survivors wanted to discuss and reported discussing in clinic, time waiting
in clinic and consultation satisfaction.
Results: There were no gender diﬀerences in number of self-reported late eﬀects or perceived
vulnerability. Men with more late eﬀects reported worse psychological HRQoL (r5 0.50,
po0.001). While men wanted to discuss more topics than they did, women were able to discuss
the topics they wanted (ANOVA, p5 0.01). Multiple regression analyses showed a shorter wait
in clinic (r50.46, p5 0.009) and discussing more topics (r5 0.34, p5 0.06) explained
30.6% of the variance in consultation satisfaction for men.
Conclusions: Issues surrounding follow-up provision are increasingly important given the length
of survival in young adults following treatment for lymphoma. Men may experience poor
psychological well-being due to distress about unanswered concerns. Consideration of their
concerns should be prioritised, given that satisfaction and ultimately continued attendance at clinic
and HRQoL may be dependent on the extent to which follow-up meets survivors’ expectations.
Copyright r 2010 John Wiley & Sons, Ltd.
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Introduction
Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s
Lymphoma (NHL) are among the most common
cancers to aﬀect young adults aged 18–45 years [1].
Over the past 20 years, cure rates have improved
rapidly, with current 5-year survival rates of approxi-
mately 80% for HL and 54–60% for NHL [2]. At
the same time, a number of physical and psycho-
logical late eﬀects have been identiﬁed, including
disorders of the endocrine system, cardiac and
pulmonary dysfunction, renal and hepatic impair-
ment, secondary malignancies, neuro-cognitive
impairment, psychological diﬃculties and gonadal
dysfunction [3–9]. The increasing numbers of survi-
vors and incidence of late eﬀects has led to calls for
long-term structured follow-up [10,11]. However, it
is important to ensure follow-up meets survivors’
expectations, and that they are satisﬁed with the care
they receive.
Physical late eﬀects may well be associated with
compromised health-related quality of life (HRQoL).
The availability of generic measures, such as
SF-36 [12], has facilitated comparison of HRQoL
of survivors relative to the general population.
Compared with norms, lymphoma survivors report
compromised physical HRQoL, but not necessarily
compromised mental HRQoL [13]. However, such
comparisons are relatively blunt and lack sensitivity
to disease-speciﬁc concerns [14,15].
Previous work has shown that better HRQoL
is associated with greater clinic satisfaction in
patients with chronic diseases in general [16],
chronic lymphocytic leukaemia [17], psoriasis [18]
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and Type II diabetes [19]. When aspects of the
clinic visit are examined in detail, poorer satisfac-
tion with doctor–patient communication has been
associated with worse HRQoL in patients with
rectal cancer [20] and coeliac disease [21]. Further-
more, these ﬁndings have implications for future
healthcare. Based on a meta-analysis of 106
studies, poor physician communication was asso-
ciated with a 19% higher risk of non-adherence to
treatment [22].
Very little work has addressed age or gender
diﬀerences in cancer concern, HRQoL or views
about follow-up. Indeed, the majority of research
on cancer survivors has focused on either older
adults or children. For young adult patients, cancer
may be considered ‘out of time’ and potentially
more stressful than for older patients as it
challenges normative goals regarding work and
reproduction [23]. Younger patients can expect
longer survival, and thus more years living with the
concerns about relapse or recurrence and the
adverse consequences of late eﬀects. Younger
patients are also more vulnerable to late eﬀects
that develop as time since treatment increases,
partly due to an increased post-treatment lifespan,
and partly because they are likely to receive more
aggressive treatment for cancer than older patients
[24–26]. However, as many as 50% of survivors of
cancer in young adulthood have reported unmet
needs regarding information about exercise, diet
and nutrition, fertility options and assistance with
health insurance [27], suggesting that attention
needs to be given to their survivorship concerns.
These unmet needs could lead to psychosocial
issues if not addressed. Although research has
suggested that older patients are more vulnerable
to a combination of late eﬀects and co-morbid
health conditions, and that planning and social
support coping decrease with age [28,29], it has
certainly been demonstrated that older and
younger patients have qualitatively diﬀerent con-
cerns [24]. There have been calls for a separate
cancer discipline focusing on improving outcomes
in treatment and survivorship among patients diag-
nosed in adolescence and young adulthood [30].
Given the speciﬁc needs of younger patients
following cancer, our focus in this study is on
those under 45 years.
Male survivors are more likely to report that
cancer adversely aﬀects their health than female
survivors [31], and male adolescent survivors report
a more negative view of the future than female
survivors [32]. Following HL, men report better
physical [33–35] and emotional functioning [34]
than women, but also more fatigue and worse
HRQoL [36]. However, female survivors of child-
hood cancer report less satisfaction with follow-up
consultations than males [37]. However, studies to
date have not necessarily considered how and why
the interaction between gender and age may impact
on people’s experiences [38]. This is important as
gender is always framed in a relational context [38],
and gender diﬀerences should therefore be assessed
within a speciﬁc age group.
It is often not possible to evaluate age or gender
diﬀerences, since many cancers are age linked oor
gender linked. Thus, given that the incidence of
lymphoma is relatively similar across genders, we
took the opportunity to evaluate gender diﬀerences
in: (i) HRQoL, late eﬀects and perceived vulner-
ability in a cohort of lymphoma survivors, (ii)
satisfaction with current care and (iii) expectations
for the clinic visit and satisfaction with the
consultation. In order to address the criticism that
most past work has not been sensitive to both
generic and disease-speciﬁc issues aﬀecting survi-
vors, we assessed both generic HRQoL [39] and
aspects of survivor-speciﬁc HRQoL [40].
Methods
Participants
A cohort of younger adults treated with curative
intent for lymphoma was recruited from the out-
patient follow-up clinic at Weston Park Hospital,
Sheﬃeld, UK. Eligibility criteria included age
(18–45 years), 45 years disease-free survival, and
current registration in the clinic. Those who were
undergoing palliative care, or had insuﬃcient
ﬂuency in English to provide written informed
consent or complete questionnaires were excluded.
In total 144 eligible patients were identiﬁed
(Figure 1). Ninety-nine eligible survivors had
follow-up appointments scheduled, of these 91
completed Time 1 questionnaires and 62 returned
Time 2 questionnaires. Forty-ﬁve were eligible for
postal recruitment, and of these 24 returned
questionnaires. In total, 115 survivors (79.9%
response rate) participated in the study. The 29
survivors (15 male: (51.7%) who did not take part,
did not signiﬁcantly diﬀer from participants in
chronological age (37.7 vs 37.7, t5 0.02, p5 0.98)
or age at diagnosis (24.8 vs 24.9, t5 0.12, p5 0.91).
Procedure
Eligible patients were identiﬁed from hospital
databases and clinic lists between December 2006
and January 2008. Those attending the hospital for
follow-up care were sent information about the
study, a consent form and a questionnaire approxi-
mately 1 week before their appointment (T1), and
asked to complete these prior to attendance.
On leaving clinic, survivors were given a second
questionnaire to complete at home (T2). Eligible
survivors not attending follow-up during the study
period were sent an information sheet, consent
form and abridged questionnaire by post. All
questionnaires completed at home were returned
Copyright r 2010 John Wiley & Sons, Ltd. Psycho-Oncology (2010)
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anonymised in freepost envelopes. At all stages,
patients were reminded that participation in the
study was voluntary, that declining to take part
would not inﬂuence their treatment, and that they
were free to withdraw from the study at any time.
The study was approved by the South Sheﬃeld
Local Research Ethics Committee, and all parti-
cipants provided written consent.
Measures
Time 1
 Demographic information
 Issues to discuss during consultations [37]:
Ten issues were listed (e.g. current health,
medication, fertility, health behaviours) and
survivors were asked if they wanted to
discuss each of these issues during their next
follow-up consultation. The total number of
issues was summed (0–10).
 Current late eﬀects and vulnerability [37]:
Eighteen possible cancer-related health pro-
blems were listed (e.g. infertility, fatigue,
depression). Participants were asked to rate
their perceived vulnerability to each late eﬀect
on a 5-point scale, from 1 (very unlikely) to 5
(very likely). A further alternative response
‘I already have this problem’, was provided.
Two scores were computed: total number of
late eﬀects currently experienced (0–18) and
vulnerability (range 1–5), where higher scores
indicate greater perceived vulnerability.
 HRQoL —Generic: The SF-12v2 [38] is a
12-item measure that yields two summary
scores: Physical component summary (PCS)
and mental component summary (MCS).
Both scales have excellent reliability and
validity [39]. Age and gender matched norms
are available.
 HRQoL—Cancer-speciﬁc: The psychological
(6 items) and social well-being (8 items) scales
were used from the QoL-CS [39]. Each item is
scored on a 7-point Likert-type scale, where
higher scores indicate worse quality of life.
Good reliability and validity have been
demonstrated [40].
Time 2
Following clinic appointments survivors completed
measures of:
 Issues discussed The same 10 issues presented
at T1 were presented, and survivors indicated
which they discussed with clinic staﬀ.
 Satisfaction with the consultation: The
Princess Margaret Hospital Satisfaction with
Doctor Questionnaire [41] is a 29-item
measure of satisfaction with outpatient con-
sultations which includes four subscales:
information exchange, interpersonal skills,
empathy and quality of time. Each item is
assessed on a 4-point scale from 1 (strongly
agree) to 4 (strongly disagree). There is a
further alternative response ‘does not apply
Figure 1. Participant recruitment
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to me’. Excellent reliability and validity have
been demonstrated [41]. In the current study,
the items were coded such that higher scores
indicated greater satisfaction with the con-
sultation. A mean score was generated for
each subscale and these were summed to
compute a mean overall satisfaction score.
 Waiting time and length of consultation:
Participants were asked to estimate time
waiting for the consultation once in clinic
and the length of their consultation.
Survivors without scheduled follow-up appoint-
ments completed an abridged postal questionnaire
that included the following described above:
 Demographic information
 Issues to discuss at their next consultation
 Current late eﬀects and vulnerability
 Generic HRQoL [39].
Medical information
Information on diagnosis, treatment and time since
end of treatment was obtained from medical records.
Analysis
Analyses were conducted using SPSS version 15.
All measures were scored according to information
in manuals or original articles. Cronbach as were
computed to assess internal reliability. As appro-
priate, Chi-square and t-tests were used to assess
gender diﬀerences in demographic variables, treat-
ment regimens, HRQoL, late eﬀects, topics survi-
vors wanted to discuss and topics discussed.
Pearson correlations were used to identify associa-
tions between HRQoL, late eﬀects and satisfaction
with the consultation. McNemar’s tests were used
to compare the proportion of survivors intending
to raise each issue during the consultation with
issues that were discussed, by gender. A mixed
ANOVA was used to assess the interaction
between gender and number of topics (wanted to
discuss and discussed). Multiple regressions were
conducted to determine predictors of satisfaction
separately for men and women.
Results
Demographic and clinical information
Demographic and clinical information about the
sample is described in Table 1, and details of
chemotherapy and radiotherapy regimens in Table 2.
The modal dosage of radiotherapy was 3500Gy
(62/85 patients, 72.9%) in 20 fractions (66/85
patients, 77.6%).
Internal reliabilities of the scales
Where considered appropriate, Cronbach’s a’s
were computed to assess internal reliability. For
the CS-QoL [40], Cronbach’s a was 0.88 for the
psychological well-being scale and 0.74 for the
social well-being scale, indicating acceptable relia-
bility. The a for the psychological well-being scale
is equivalent to that in the validation study, but
Table 1. Means (SD) for demographic and clinical information
by gender
Male
(n557)
Female
(n558)
Overall
(N5115)
Demographics
Age 37.5 (5.8) 37.9 (5.6) 37.7 (5.6)
Years since end of
treatment
11.4 (4.5) 12.0 (5.3) 11.7 (4.9)
Time since diagnosis 12.4 (4.6) 13.1 (5.5) 12.8 (5.0)
Diagnosis (N, %)
Hodgkin lymphoma 46 (80.7%) 51 (87.9%) 97 (84.3%)
Non-Hodgkin
lymphoma
11 (19.3%) 7 (12.1%) 18 (15.7%)
Treatment (N, %)
Surgery 50 (87.7%) 56 (96.6%) 107 (93%)
Chemotherapy 49 (86%) 51 (87.9%) 100 (87%)
Radiotherapy 39 (68.4%) 46 (79.3%) 85 (73.9%)
Employment status (N, %)
Full-time 46 (80.7%) 31 (53.4%) 77 (67%)a
Part-time 1 (1.8%) 20 (34.5%) 21 (18.3%)b
Sick leave 1 (1.8%) 1 (1.7%) 2 (1.7%)
Student 1 (1.8%) 2 (3.4%) 3 (2.6%)
Homemaker 1 (1.8%) 2 (3.4%) 3 (2.6%)
Retired 1 (1.8%) 0 1 (0.9%)
Unemployed 3 (5.3%) 2 (3.4%) 5 (4.3%)
Marital status (N, %)
Single 13 (22.8%) 9 (15.5%) 22 (19.1%)
Married/living with
partner
41 (71.9%) 44 (75.9%) 85 (73.9%)
Divorced/separated 3 (5.3%) 5 (8.6%) 8 (7%)
aMen were more likely to be working full-time (w2 (1)5 13.1, po0.001).
bWomen were more likely to be working part-time (w2 (1)5 19.5, po0.001).
Table 2. Chemotherapy regimens (N, %) by gender
Regimen Male Female Overall
ABVD 5/49 (10.2%) 8/51 (15.7%) 13/100 (13%)
ChLVPP
(alone/in combination)
16/49 (32.7%) 16/51 (31.4%) 32/100 (32%)
CHOP
(alone/in combination)
7/49 (14.3%) 5/51 (9.8%) 12/100 (12%)
LOPP
(alone/in combination)
7/49 (14.3%) 11/51 (21.6%) 18/100 (18%)
Other 14/49 (28.6%) 11/51 (21.6%) 25/100 (25%)
Radiotherapy—mantle/
mediastinum/neck
28/39 (71.8%) 42/46 (91.3%) 70/85 (82.3%)a
Radiotherapy–other
part of body
11/39 (28.2%) 4/46 (8.7%) 15/85 (17.6%)
ABVD, Adriamycin, bleomycin, vinblastine, dacarbazine; ChLVPP, Chlorambucil,
vinblastine, procarbazine, prednisone; CHOP, Cyclophosphamide, Adriamycin,
Vincristine, Prednisone; LOPP, Chlorambucil, vincristine, procarbazine, prednisone.
aMore women than men had received mantle field radiotherapy: 91 vs 72%;
(w2 (1)5 5.53, p5 0.02).
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that of the social well-being scale is lower than that
of 0.81 demonstrated in the validation study [40].
In order to determine that the scale was gender
appropriate (the original sample included 80%
women), we ran Cronbach as separately by gender.
This showed the a for the social well-being scale
was higher for men (0.77) than for women (0.67).
There were no major diﬀerences in the psycho-
logical well-being scale. For the Satisfaction with
Doctor Questionnaire, Cronbach’s a for the overall
scale was 0.96, indicating excellent reliability. as for
the subscales were comparable in the validation
and current studies, respectively: interpersonal
skills: 0.89 vs 0.90, information exchange: 0.89 vs
0.92, quality of time: 0.92 vs 0.88, and empathy:
0.93 vs 0.88, indicating excellent reliability [41].
Again, when broken down by gender, overall as
were similar for men (0.97) and women (0.96),
indicating excellent reliability.
(i) HRQoL, late eﬀects and perceived vulnerability.
HRQoL scores are shown in Table 3. Survivors
compared favourably with age- and gender-matched
norms on both the PCS and MCS [32]. There were
no gender diﬀerences on PCS or MCS or for psycho-
logical and social HRQoL on the CS-QoL [40].
Seventy two (62.6%) survivors reported one or
more late eﬀects (mean5 2.0), including fertility
(27%), thyroid dysfunction (22.6%), chronic fati-
gue (17.4%) and mood swings (17.4%) (Table 4).
Late eﬀects diﬀered by gender: the most common
for women were thyroid dysfunction (32.8%),
fertility (29.3%) and chronic fatigue (20.7%),
whereas the most common for men were fertility
(24.6%), mood swings (17.5%) and weight gain
(15.8%). Higher perceived vulnerability to late
eﬀects was associated with worse MCS scores (SF-
12) in men (r50.41, p5 0.003), but not women.
Based on the QoL-CS, men who reported more late
eﬀects also reported worse psychological (r5 0.50,
po0.001), and social (r5 0.40, p5 0.007) quality
of life. Men who reported greater perceived
vulnerability to late eﬀects also reported worse
social quality of life (r5 0.38, p5 0.01).
More reported late eﬀects (r50.35, po0.001)
and higher perceived vulnerability to late eﬀects
(r50.24, p5 0.01) were associated with worse
PCS scores. Based on the QoL-CS, worse psycho-
logical quality of life was associated with more
reported late eﬀects (r5 0.26, p5 0.01), and greater
perceived vulnerability to late eﬀects (r5 0.44,
po0.001).
(ii) Satisfaction with current care
T2 questionnaires were completed by 62 of the
115 survivors. There were no diﬀerences between
responders and non-responders, except that time
since diagnosis was shorter for responders (11.9 vs
13.8 years, t (113)5 2.00, po0.05).
Overall satisfaction was high (mean53.5,
SD50.5). There were no diﬀerences between genders
in satisfaction on the overall scale or on individual
subscales measuring information exchange, inter-
personal skills, empathy and quality of time. Length
of wait and length of consultation are reported in
Table 5. The modal length of wait was 0–20min, and
the modal length of consultation was 6–10min.
(iii) Expectations for the clinic visit and satisfac-
tion with the consultation.
Percentages of survivors who wanted to discuss
and discussed particular topics are reported in Table 6.
Table 3. HRQoL [Mean (SD)] by gender
Scale Men Men norm Women Women norm Overall
SF-12
MCS 50.2(7.9) 50.1 (0.2) 47.6 (10.4) 47.5 (0.7) 48.9 (9.3)
PCS 52.1 (8.0) 53.0 (0.6) 52.8 (9.3) 51.5 (0.9) 52.4 (8.7)
QoL-CS
Psychological 2.5 (1.5) 2.2 (1.5) 2.4 (1.5)
Social 1.8 (1.1) 1.5 (0.9) 1.6 (1.0)
Table 4. Self reported late effects by gender (N, %)
Late effect Men
(n5 57)
Women
(n5 58)
Overall
(N5115)
Fertility 14 (24.6%) 17 (29.3%) 31 (27%)
Thyroid dysfunction 7 (12.3%) 19 (32.8%) 26 (22.6%)
Chronic fatigue 8 (14%) 12 (20.7%) 20 (17.4%)
Mood swings 10 (17.5%) 10 (17.2%) 20 (17.4%)
Depression 8 (14%) 7 (12.1%) 15 (13%)
Damage to testes/ovaries 6 (10.5%) 9 (15.5%) 15 (13%)
Weight gain 9 (15.8%) 6 (10.3%) 15 (13%)
Lung 5 (8.8%) 8 (13.8%) 13 (11.3%)
Lymphoedema 6 (10.5%) 4 (6.9%) 10 (8.7%)
Sight 7 (12.3%) 3 (5.2%) 10 (8.7%)
Memory 6 (10.5%) 4 (6.9%) 10 (8.7%)
Sexual functioning 3 (5.3%) 4 (6.9%) 7 (6.1%)
Hearing 5 (8.8%) 1 (1.7%) 6 (5.2%)
Osteoporosis 1 (1.8%) 2 (3.4%) 3 (2.6%)
Second cancer 1 (1.8%) 1 (1.7%) 2 (1.7%)
Diabetes 1 (1.8%) 0 1 (0.9%)
Heart 0 0 0
Liver 0 0 0
11problem reported 32 (56.1%) 40 (69%) 72 (62.6%)
Mean number of
late effects (SD)
1.7 (2.0) 1.8 (1.9) 1.8 (2.0)
Mean perceived
vulnerability (SD)
2.6 (0.6) 2.8 (0.7) 2.7 (0.6)
Gender differences in quality of life following lymphoma 5
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As shown in Table 6, both men and women most
wanted to address late eﬀects of treatment, current
health and current health behaviours in the
consultation. The most common topics discussed
were current health, late eﬀects of treatment and
current health behaviours for men, and current
health, late eﬀects of treatment and medication for
women. Both men and women wanted to discuss
late eﬀects of treatment signiﬁcantly more than
they did (Men: 80.6 vs 29%, po0.001; Women:
80.6 vs 48.4%, p5 0.002). Men also wanted to
discuss insurance and current health behaviours
signiﬁcantly more than they did (Insurance: 32.3%
vs 0, p5 0.01; Current health behaviours: 67.7 vs
38.7%, p5 0.04). More men than women wanted
to discuss current health behaviours (67.7 vs
32.2%; w25 7.81, p5 0.005). Women who wanted
to discuss more topics reported that more topics
were discussed in the consultation (r5 0.50,
p5 0.004) and also perceived greater vulnerability
to late eﬀects (r5 0.41, p5 0.006). There were no
similar results for men.
A mixed ANOVA with number of topics
(wanted to discuss, discussed) as the within subjects
factor and gender as the between subjects factor
revealed (i) a signiﬁcant main eﬀect of number of
topics (F(1, 60)5 6.22, p5 0.015), indicating
that survivors wanted to discuss more topics
(Mean5 3.3) than they did (Mean5 2.5), and (ii)
a signiﬁcant gender by number of topics interaction
(F(1, 60)5 6.83, p5 0.01), indicating that while
men wanted to discuss more topics than they
discussed, women were able to discuss the topics
they wanted.
Correlations between satisfaction with the con-
sultation and a variety of other variables were run
for the overall sample and by gender. For the
overall sample, survivors who reported being more
satisﬁed with their consultation had waited a
shorter time (r50.32, p5 0.01). No correlates
of satisfaction were identiﬁed for women. For men,
the only correlates of satisfaction were waiting time
(men who were more satisﬁed reported waiting a
shorter time once in the waiting room: r50.46,
p5 0.009) and number of topics discussed (men
who were more satisﬁed tended to have discussed
more topics in the consultation: r5 0.34, p5 0.06).
Importantly, there was no relation between work-
ing full-time and satisfaction with the consultation.
In a multiple regression carried out on men only,
number of topics discussed and waiting time were
entered as independent variables and explained
30.6% of the variance in satisfaction with the
consultation (F(2, 28)5 6.17, p5 0.006).
Discussion
The young adult lymphoma survivors in this study
reported MCS and PCS comparable to age-and
gender-matched norms, even though approximately
two-thirds reported one or more late eﬀects of their
Table 5. Length of wait before consultation and length of the consultation (N, %)
Variable Minutes Male (n531) Female (n531) Overall (N562)
Length of wait 0–20 19 (61.3%) 17 (54.8%) 36 (58.1%)
21–30 3 (9.7%) 8 (25.8%) 11 (17.7%)
31–60 8 (25.8%) 5 (16.1%) 13 (18.3%)
61–90 1 (3.2%) 1 (3.2%) 2 (3.2%)
Length of consultation 0–5 9 (29.0%) 3 (9.7%) 12 (19.4%)
6–10 13 (41.9%) 15 (48.4%) 28 (45.2%)
11–20 6 (19.4%) 13 (41.9%) 19 (30.6%)
21–30 3 (9.7%) 0 3 (4.8%)
Table 6. Discrepancy between topics survivors wanted to discuss and topics discussed, by gender (N, %)
Topic Men Women
Wanted to
discuss
Discussed McNemar Test
(exact sig)
Wanted to
discuss
Discussed McNemar Test
(exact sig)
Current health 27 (87.1%) 28 (90.3%) 1 23 (74.2%) 28 (90.3%) 0.13
LE of treatment 25 (80.6%) 9 (29.0%) o0.001 AQ1 25 (80.6%) 15 (48.4%) 0.002
Medication 9 (29.0%) 8 (25.8%) 1 5 (16.1%) 12 (38.7%) 0.07
Current health behaviours 21 (67.7%) 12 (38.7%) 0.04 10 (32.3%) 7 (22.6%) 0.73
Fertility 10 (32.3%) 4 (12.9%) 0.07 10 (32.3%) 4 (12.9%) 0.07
Work/education 5 (16.1%) 5 (16.1%) 1 3 (9.7%) 4 (12.9%) 1
Contraception 3 (9.7%) 0 0.25 1 (3.2%) 0 1
Sexual problems 4 (12.9%) 2 (6.5%) 0.50 1 (3.2%) 0 1
Insurance 10 (32.3%) 0 0.01 6 (19.4%) 0 0.06
Overall number of topics to discuss 3.7 2.3 t (30)5 3.0, p5 0.005 2.6 2.7 t (30)50.11 p5 0.91
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cancer. Apart from thyroid problems, an established
consequence of mantle ﬁeld radiation, [42], men and
women reported similar numbers of late eﬀects. Not
surprisingly, those who self-reported more late
eﬀects, and rated themselves as more vulnerable to
late eﬀects also reported worse physical HRQoL, as
measured by a generic scale. Good reliability and
validity had previously been reported for all scales,
and good to excellent reliability (Cronbach’s a) was
demonstrated in the current study, both for the
overall sample, and when the results were broken
down by gender. These ﬁndings suggest that the
measures used were appropriate for the population
in question. The only area of concern is that for
women, the social well-being scale of the QoL-CS
demonstrated slightly below adequate reliability,
and thus future studies should consider the removal
of speciﬁc items as appropriate.
Overall, high levels of satisfaction with the
consultation were reported (mean 3.5 out of 4).
Despite this, survivors wanted to discuss a range of
issues, such as current health, advice on health
behaviours, late eﬀects of treatment, and insurance,
which tended to be addressed less frequently than
was wanted. Both men and women wanted to
discuss late eﬀects of treatment signiﬁcantly more
than they did, and men wanted more advice on
current health behaviours and insurance, and to
discuss signiﬁcantly more topics overall than they
did. Although the questionnaires were returned
anonymously and patients were expressly informed
that participation would not inﬂuence their treat-
ment, it is possible (though unlikely) they might
have had concerns that negative evaluation would
jeopardise their follow-up.
Notwithstanding time constraints in clinic, our
study suggests that survivors want to discuss late
eﬀects. There have also been recommendations for
discussions to address the need for a healthy lifestyle
to reduce morbidity and mortality in cancer
survivors [43], particularly men, who are less likely
to engage in good health practices than women [44].
It is also important to address fertility concerns, and
patients (especially men) should be advised of recent
advances in assisted conception and availability of
fertility testing [45]. Leaﬂets advising patients on
insurance would also be helpful, even if there is no
time to discuss this in the consultation. Appropriate
leaﬂets giving advice about late eﬀects, similar to
those developed by the Children’s Cancer and
Leukaemia Group (CCLG) might be helpful:
(http://www.cclg.org.uk/index.php).
Those who were more satisﬁed with their
consultations reported shorter waiting times. This
was the case even though those who had waited
longer tended to report longer consultations. There
was no association between perceived length of
consultation and number of topics discussed,
implying that time constraints are not necessarily
a barrier to eﬀective consultations.
A number of gender diﬀerences were identiﬁed.
First, men, but not women, who reported greater
perceived vulnerability to late eﬀects reported poorer
MCS. In addition, men who reported more late
eﬀects also reported worse psychological and social
quality of life based on the survivor-speciﬁc QoL-CS.
Despite this, men discussed signiﬁcantly fewer issues
than they wished, while women discussed the same
number of topics as they wanted. Thus, men may
experience poor psychological well-being as a con-
sequence of distress about unanswered concerns.
In support of this explanation, a qualitative study of
men newly diagnosed with cancer revealed high levels
of unmet information needs [46]. Men themselves
may be more reluctant or lack conﬁdence to raise
concerns in clinic compared with women. A potential
explanation for this result is the ‘ﬁxed role’ hypo-
thesis of gender and health [47], which suggests that
women are socialised to seek medical help, whereas
men are taught early in their lives to manifest stoicism
[48]. It is also possible that doctors are less likely to
address men’s concerns in depth. Physicians generally
provide more information, support and reassurance
when patients ask questions, oﬀer opinions and
express concerns [49], which are more commonly
assumed to be feminine characteristics [49]. Either
way, it may be important to address gender-based
stereotypes suggesting that men are more stoic, self
suﬃcient or simply do not need to discuss issues to a
similar extent as women [49–54], particularly as
masculine characteristics, such as inexpressiveness,
have been shown to be a signiﬁcant predictor of poor
health in men [50]. Only by addressing such
stereotypes will it be possible to address men’s
concerns about their illness or provide opportunities
for health promotion and lifestyle change.
Second, women, but not men who reported
greater vulnerability to late eﬀects wanted to discuss
more topics, suggesting that they view the consulta-
tion as an opportunity for reassurance. Third, the
relation between greater satisfaction with the con-
sultation and shorter waiting time held only for men.
Men who are newly diagnosed with cancer also
report feeling uncomfortable in the hospital setting
and wanting their consultation to ﬁnish as quickly as
possible [46]. This again ﬁts with recent theorising
about gender, which suggests that men traditionally
refuse to admit weakness, which creates gender role
conﬂict in situations of vulnerability [55]. As some
waiting times are inevitable in busy oncology units,
research is needed to explore how to help men feel
more relaxed in the hospital. Fourth, men who were
more satisﬁed with their consultation tended to have
discussed more topics. This ﬁnding is of special
signiﬁcance in that men discussed signiﬁcantly fewer
issues than they wanted.
The strengths of this study include recruitment
across a relatively narrow age group, who are likely
to have similar issues of concern [24], a consequence
of their young age at diagnosis, and associated
Gender differences in quality of life following lymphoma 7
Copyright r 2010 John Wiley & Sons, Ltd. Psycho-Oncology (2010)
DOI: 10.1002/pon
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
UN
CO
RR
EC
TE
D 
PR
OO
F
disruption of life goals. The majority experienced
similar treatment (almost all had surgery and
chemotherapy), with the likelihood of common late
eﬀects. Diﬀerent results may be found for those
from diﬀerent age groups.
Inevitably there were a number of limitations with
this study. First, details of late eﬀects and topics
discussed during consultations were obtained from
survivors’ reports only, and not conﬁrmed in
medical records. Signiﬁcant diﬀerences between
survivor reported late eﬀects and those in medical
notes have been reported [56] as well as considerable
discrepancies between doctor and patient recollec-
tion of medical consultations [57]. Second, the
sample was relatively small and recruited from a
single cancer centre, and thus may not be represen-
tative of all patients with lymphoma. Third, details
of the consulting clinician (e.g. gender, experience)
were not recorded, which meant diﬀerences in
consultation style could not be examined. It is also
possible that clinician gender may aﬀect male
patients’ willingness to discuss issues. Previous work
suggests that both male and female patients tend to
talk more and ask more questions when interacting
with female health-care professionals [49].
Given increasing number of survivors, length of
survival and prevalence of late eﬀects, questions
about appropriate follow-up are highly topical. Our
results suggest that survivors’ satisfaction is related to
practical issues including waiting time, but also
aspects of the consultation, especially opportunities
to ask questions. Men seem especially intolerant of
lengthy waiting times, and less likely than women to
ask questions. More qualitative studies are needed to
determine the dynamics between doctors and patients
in clinic consultations in order to clarify if men are
reluctant to initiate discussions about their concerns,
or whether doctors provide fewer opportunities for
men. Improved understanding of any gender diﬀer-
ences could lead to better management of late eﬀects
and approaches to health promotion among cancer
survivors. As with survivors of other cancers, the
wide range of follow-up needs in lymphoma
survivors challenges provision of follow-up.
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